相关实验视频
Updated: Jun 14, 2025
06:03
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
9.0K
基于干扰RNA (RNAi) 的治疗方法在心力衰竭中的安全性和有效性:系统性审查
Muhammad Nabeel Saddique1, Maria Qadri2, Noor Ul Ain3
1King Edward Medical University, Lahore 54000, Pakistan.
Heart & lung : the journal of critical care
|August 30, 2024
概括
RNAi疗法为心力衰竭提供了一个有前途的新疗法,在改善心脏功能和生物标志物方面显示出有效性,副作用最小. 需要进一步的研究来优化交付和长期安全.
科学领域:
- 心血管医学 心血管医学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 心力衰竭是全球重要的健康问题,也是导致死亡的主要原因.
- 抗RNA干扰 (RNAi) 疗法为因非标效应和缺乏特异性而对传统治疗无反应的患者提供了潜在的替代方案.
研究的目的:
- 评估RNAi疗法在治疗心力衰竭中的安全性和有效性.
- 综合现有关于心血管疾病的RNAi干预措施的研究.
主要方法:
- 在PubMed,Embase,Scopus和Cochrane数据库中进行了全面的文献搜索.
- 为了进行定性综合,包括了14项研究,涵盖从研究开始到2023年12月31日的研究.
主要成果:
- 帕蒂西兰和复苏西兰在心脏粉症患者的心脏输出和左心室壁厚度显著改善.
- 在各种模型中,RNAi疗法,包括Nox2-siRNA,DUSP5 siRNA + T3和meg3抑制,在恢复心脏功能和改善心脏生物标志物方面表现出有效性.
- 副作用是最小的,包括外围神经病变和轻度心脏毒性,观察到心脏生物标志物的整体改善.
结论:
- RNAi疗法是增强心脏功能的新选择,因为它们具有高的向特异性和能够解决以前无法向的基因.
- 建议进行进一步的研究,以优化RNAi传递,增强目标特异性,评估长期安全性和确定成本效益.
相关概念视频
02:15Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
02:30siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545